Sandra Milligan
CIK: 0001859810
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Sep 23, 2026GOSS
Gossamer Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
10K shares- - Jun 4, 2026GOSS
Gossamer Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
115K shares- - May 27, 2026SYRE
Spyre Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
8K shares- - Aug 19, 2025GOSS
Gossamer Bio, Inc.
Purchase(P)Direct26.1K shares at avg. $1.92$50K - Jun 25, 2025GOSS
Gossamer Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
115K shares- - May 29, 2025SYRE
Spyre Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
25K shares- - Jan 8, 2025AWH
Aspira Women's Health Inc.
Tax Payment(F)Direct6.4K shares at avg. $0.70$4K - Dec 31, 2024AWH
Aspira Women's Health Inc.
Exercise(M)Direct20K shares- - Dec 31, 2024AWH
Aspira Women's Health Inc.
Exercise(M)DirectRestricted Stock Units
20K shares- - Nov 12, 2024AWH
Aspira Women's Health Inc.
Award(A)DirectStock option (right to buy)
25K shares- - Oct 28, 2024AWH
Aspira Women's Health Inc.
Award(A)DirectRestricted Stock Units
20K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 23, 2026 |  GOSS Gossamer Bio, Inc. | Award(A) Stock Option (Right to Buy) | 10,000 | - | - | Direct |
| Jun 4, 2026 | GOSS Gossamer Bio, Inc. | Award(A) Stock Option (Right to Buy) | 115,000 | - | - | Direct |
| May 27, 2026 |  SYRE Spyre Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 8,026 | - | - | Direct |
| Aug 19, 2025 | GOSS Gossamer Bio, Inc. | Purchase(P) | 26,050 | $1.92 | $50,016 | Direct |
| Jun 25, 2025 | GOSS Gossamer Bio, Inc. | Award(A) Stock Option (Right to Buy) | 115,000 | - | - | Direct |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 25,000 | - | - | Direct |
| Jan 8, 2025 |  AWH Aspira Women's Health Inc. | Tax Payment(F) | 6,356 | $0.70 | $4,449 | Direct |
| Dec 31, 2024 | AWH Aspira Women's Health Inc. | Exercise(M) | 20,000 | - | $0 | Direct |
| Dec 31, 2024 | AWH Aspira Women's Health Inc. | Exercise(M) Restricted Stock Units | 20,000 | - | - | Direct |
| Nov 12, 2024 | AWH Aspira Women's Health Inc. | Award(A) Stock option (right to buy) | 25,000 | - | - | Direct |
| Oct 28, 2024 | AWH Aspira Women's Health Inc. | Award(A) Restricted Stock Units | 20,000 | - | - | Direct |
1-11 of 11 transactions
About Milligan Sandra
Milligan Sandra (SEC CIK 0001859810) files insider reports with the SEC as Director of Gossamer Bio, Inc. (GOSS), Director of Spyre Therapeutics, Inc. (SYRE) and Interim CEO & President of Aspira Women's Health Inc. (AWH).
Signal8 holds 10 ownership filings by Milligan Sandra, all Form 4s, filed between Oct 28, 2024 and Sep 25, 2026. Those filings report 11 transactions, from Oct 28, 2024 to Sep 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Milligan Sandra's filings is in SAN DIEGO, CA.
Recent filings by Milligan Sandra
- Sep 23, 2026: Grant or award of GOSS derivative securities (Form 4, code A).
- Jun 4, 2026: Grant or award of GOSS derivative securities (Form 4, code A).
- May 27, 2026: Grant or award of SYRE derivative securities (Form 4, code A).
- Aug 19, 2025: Open-market purchase of GOSS shares (Form 4, code P).
- Jun 25, 2025: Grant or award of GOSS derivative securities (Form 4, code A).
Other insiders filing for Gossamer Bio, Inc. (GOSS)
- Daniel Thomas O, Director
- Ciongoli Gregory Austin, Director
- Drynan Skye, Director
- Quisel John D, Director
- Cox Russell J., Director
- Nathan Steven D, Director